Munich - Delayed Quote EUR
Genscript Biotech Corp (G51.MU)
1.2505
+0.0040
+(0.32%)
At close: May 2 at 8:04:21 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
594,486
594,486
560,480
625,698
490,096
Cost of Revenue
322,361
322,361
289,851
321,615
207,578
Gross Profit
272,125
272,125
270,629
304,083
282,518
Operating Expense
249,411
249,411
230,445
731,839
651,730
Operating Income
22,714
22,714
40,184
-427,756
-369,212
Net Non Operating Interest Income Expense
20,862
20,862
16,845
-51
407
Pretax Income
-170,797
-170,797
168,885
-431,690
-517,363
Tax Provision
2,977
2,977
6,006
-3,719
964
Net Income Common Stockholders
2,961,877
2,961,877
-95,477
-226,851
-358,712
Diluted NI Available to Com Stockholders
2,961,877
2,961,877
-95,477
-226,851
-358,712
Basic EPS
1.40
--
-0.05
-0.11
-0.18
Diluted EPS
1.36
--
-0.05
-0.11
-0.18
Basic Average Shares
2,121,285.4540
--
2,109,365.3280
2,097,134.7000
2,030,597.5790
Diluted Average Shares
2,178,301.7400
--
2,202,472.7070
2,097,134.7000
2,030,597.5790
Total Expenses
571,772
571,772
520,296
1,053,454
859,308
Net Income from Continuing & Discontinued Operation
2,961,877
2,961,877
-95,477
-226,851
-358,712
Normalized Income
-26,049.4900
-26,049.4900
436,676.1180
-232,938.1040
-259,141.4600
Interest Income
28,894
28,894
22,584
13,218
2,785
Interest Expense
8,032
8,032
5,739
13,269
2,378
Net Interest Income
20,862
20,862
16,845
-51
407
EBIT
-162,765
-162,765
174,624
-418,421
-514,985
EBITDA
-85,095
-85,095
248,670
-354,173
-467,206
Reconciled Cost of Revenue
322,361
322,361
289,851
321,615
207,578
Reconciled Depreciation
77,670
77,670
74,046
64,248
47,779
Net Income from Continuing Operation Net Minority Interest
-67,184
-67,184
422,523
-226,851
-358,712
Total Unusual Items Excluding Goodwill
-52,069
-52,069
-14,675
6,140
-136,398
Total Unusual Items
-52,069
-52,069
-14,675
6,140
-136,398
Normalized EBITDA
-33,026
-33,026
263,345
-360,313
-330,808
Tax Rate for Calcs
0.0002
0.0002
0
0
0.0003
Tax Effect of Unusual Items
-10,934.4900
-10,934.4900
-521.8820
52.8960
-36,827.4600
12/31/2021 - 6/16/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade